The effect of activated protein C on plasma cytokine levels in a porcine model of acute endotoxemia

Intensive Care Medicine

Volumn 33, Issue 6, 2007, Pages 1085-1093

  Nielsen, Jeppe Sylvest ^a   Larsson, Anders ^b   Rix, Thomas ^a   Nyboe, Rasmus ^a   Gjedsted, Jakob ^a   Krog, Jan ^a   Ledet, Thomas ^a   Tønnesen, Else ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Cytokines; Drotrecogin alfa; Endotoxemia; Protein C; Sepsis; Systemic inflammatory response syndrome

Indexed keywords

BIOLOGICAL MARKER; CYTOKINE; DROTRECOGIN; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TUMOR NECROSIS FACTOR ALPHA;

ACUTE DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD CLOTTING; CONTINUOUS INFUSION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; ENDOTOXEMIA; FEMALE; FIBRINOLYSIS; HEMODYNAMIC PARAMETERS; LEUKOCYTE COUNT; METABOLIC PARAMETERS; NONHUMAN; PROTEIN BLOOD LEVEL; RANDOMIZATION; SWINE;

ANIMALS; CYTOKINES; DENMARK; ENDOTOXEMIA; PROTEIN C; RANDOM ALLOCATION; RECOMBINANT PROTEINS; SWINE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 34249735244     PISSN: 03424642     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00134-007-0631-1     Document Type: Article

References (36)

1. Brun-Buisson C, Meshaka P, Pinton P, Vallet B (2004) EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units. Intensive Care Med 30:580-588
2. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR (2001) Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29:1303-1310
3. Taylor FB Jr, Chang A, Esmon CT, D'Angelo A, Vigano-D'Angelo S, Blick KE (1987) Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 79:918-925
4. Faust SN, Levin M, Harrison OB, Goldin RD, Lockhart MS, Kondaveeti S, Laszik Z, Esmon CT, Heyderman RS (2001) Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 345:408-416
5. Sajan I, Da-Silva SS, Dellinger RP (2004) Drotrecogin alfa (activated) in an infant with gram-negative septic shock. J Intensive Care Med 19:51-55
6. White B, Livingstone W, Murphy C, Hodgson A, Rafferty M, Smith OP (2000) An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia. Blood 96:3719-3724
7. Rintala E, Kauppila M, Seppala OP, Voipio-Pulkki LM, Pettila V, Rasi V, Kotilainen P (2000) Protein C substitution in sepsis-associated purpura fulminans. Crit Care Med 28:2373-2378
8. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699-709
9. Mackenzie AF (2005) Activated protein C: do more survive? Intensive Care Med 31:1624-1626
10. Vincent JL (2006) Sepsis in the ICU: who needs progress? Intensive Care Med 32:609
11. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Penzes I, Kubler A, Knaub S, Keinecke HO, Heinrichs H, Schindel F, Juers M, Bone RC, Opal SM (2001) Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 286:1869-1878
12. Fourrier F, Jourdain M, Tournois A, Caron C, Goudemand J, Chopin C (1995) Coagulation inhibitor substitution during sepsis. Intensive Care Med 21 (Suppl 2):S264-S268
13. Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL, Beale R, Svoboda P, Laterre PF, Simon S, Light B, Spapen H, Stone J, Seibert A, Peckelsen C, De DC, Postier R, Pettila V, Artigas A, Percell SR, Shu V, Zwingelstein C, Tobias J, Poole L, Stolzenbach JC, Creasey AA (2003) Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 290:238-247
14. Nielsen JS, Larsson A, Rix T, Nyboe R, Gjedsted J, Krog J, Ledet T, Tønnesen E (2006) Activated protein C's effects on plasma cytokines during acute endotoxemia in pigs. Intensive Care Med 32(13):74
15. Brix-Christensen V, Andersen SK, Andersen R, Mengel A, Dyhr T, Andersen NT, Larsson A, Schmitz O, Orskov H, Tonnesen E (2004) Acute hyperinsulinemia restrains endotoxin-induced systemic inflammatory response: an experimental study in a porcine model. Anesthesiology 100:861-870
16. Fourrier F, Jourdain M, Tournoys A, Gosset P, Mangalaboyi J, Chopin C (1998) Effects of a combined antithrombin III and protein C supplementation in porcine acute endotoxic shock. Shock 10:364-370
17. Murakami K, Okajima K, Uchiba M, Johno M, Nakagaki T, Okabe H, Takatsuki K (1997) Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production. Am J Physiol 272:L197-L202
18. Favory R, Lancel S, Chal X, Tissier S, Neviere R (2006) Cardiovascular protective role for activated protein C during endotoxemia in rats. Intensive Care Med 32:899-905
19. Kalil AC, Coyle SM, Um JY, LaRosa SP, Turlo MA, Calvano SE, Sundin DP, Nelson DR, Lowry SF (2004) Effects of drotrecogin alfa (activated) in human endotoxemia. Shock 21:222-229
20. Spiel AO, Firbas C, Mayr FB, Leitner JM, Schmidt B, Knobl P, Varadi K, Jilma B (2005) The effects of supra-normal protein C levels on markers of coagulation, fibrinolysis and inflammation in a human model of endotoxemia. Thromb Haemost 94:1148-1155
21. Derhaschnig U, Reiter R, Knobl P, Baumgartner M, Keen P, Jilma B (2003) Recombinant human activated protein C (rhAPC drotrecogin alfa [activated]) has minimal effect on markers of coagulation, fibrinolysis, and inflammation in acute human endotoxemia. Blood 102:2093-2098
22. Monnet X, Lamia B, Anguel N, Richard C, Bonmarchand G, Teboul JL (2005) Rapid and beneficial hemodynamic effects of activated protein C in septic shock patients. Intensive Care Med 31:1573-1576
23. Zeng W, Matter WF, Yan SB, Um SL, Vlahos CJ, Liu L (2004) Effect of drotrecogin alfa (activated) on human endothelial cell permeability and Rho kinase signaling. Crit Care Med 32:S302-S308
24. White B, Schmidt M, Murphy C, Livingstone W, O'Toole D, Lawler M, O'Neill L, Kelleher D, Schwarz HP, Smith OP (2000) Activated protein C inhibits lipopolysaccharide-induced nuclear translocation of nuclear factor kappaB (NF-kappaB) and tumour necrosis factor alpha (TNF-alpha) production in the THP-1 monocytic cell line. Br J Haematol 110:130-134
25. Joyce DE, Gelbert L, Ciaccia A, DeHoff B, Grinnell BW (2001) Gene expression profile of antithrombotic protein c defines new mechanisms modulating inflammation and apoptosis. J Biol Chem 276:11199-11203
26. Hancock WW, Grey ST, Hau L, Akalin E, Orthner C, Sayegh MH, Salem HH (1995) Binding of activated protein C to a specific receptor on human mononuclear phagocytes inhibits intracellular calcium signaling and monocyte-dependent proliferative responses. Transplantation 60:1525-1532
27. Grey ST, Tsuchida A, Hau H, Orthner CL, Salem HH, Hancock WW (1994) Selective inhibitory effects of the anticoagulant activated protein C on the responses of human mononuclear phagocytes to LPS, IFN-gamma, or phorbol ester. J Immunol 153:3664-3672
28. Hoffmann JN, Vollmar B, Laschke MW, Inthorn D, Fertmann J, Schildberg FW, Menger MD (2004) Microhemodynamic and cellular mechanisms of activated protein C action during endotoxemia. Crit Care Med 32:1011-1017
29. Grinnell BW, Hermann RB, Yan SB (1994) Human protein C inhibits selectin-mediated cell adhesion: role of unique fucosylated oligosaccharide. Glycobiology 4:221-225
30. Nick JA, Coldren CD, Geraci MW, Poch KR, Fouty BW, O'Brien J, Gruber M, Zarini S, Murphy RC, Kuhn K, Richter D, Kast KR, Abraham E (2004) Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis. Blood 104:3878-3885
31. Sakata Y, Loskutoff DJ, Gladson CL, Hekman CM, Griffin JH (1986) Mechanism of protein C-dependent clot lysis: role of plasminogen activator inhibitor. Blood 68:1218-1223
32. Bajzar L, Nesheim ME, Tracy PB (1996) The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood 88:2093-2100
33. Urano T, Castellino FJ, Ihara H, Suzuki Y, Ohta M, Suzuki K, Mogami H (2003) Activated protein C attenuates coagulation-associated over-expression of fibrinolytic activity by suppressing the thrombin-dependent inactivation of PAI-1. J Thromb Haemost 1:2615-2620
34. Munster AM, Olsen AK, Bladbjerg EM (2002) Usefulness of human coagulation and fibrinolysis assays in domestic pigs. Comp Med 52:39-43
35. Esmon CT (2004) Why do animal models (sometimes) fail to mimic human sepsis? Crit Care Med 32:S219-S222
36. Macias WL, Yan SB, Williams MD, Um SL, Sandusky GE, Ballard DW, Planquois JM (2005) New insights into the protein C pathway: potential implications for the biological activities of drotrecogin alfa (activated). Crit Care 9(Suppl 4):S38-S45